New eczema drug shows promise in Mid-Stage trial
NCT ID NCT07399067
First seen Feb 16, 2026 · Last updated May 22, 2026 · Updated 13 times
Summary
This study tests a new medicine called IBI3002 for people with moderate to severe atopic dermatitis (eczema). About 120 adults will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching. The main goal is to measure improvement in eczema severity after 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100192, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.